Official Title
Expanded Access for AG-221
Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provideaccess to AG-221.
Detailed Description
Not Provided
No longer available
Individual Patients
Acute Myeloid Leukemia
Drug: AG-221
Oral AG-221 administered as directed by treating physician.
Other Name: CC-90007; Enasidenib; Idhifa
Eligibility Criteria
Inclusion Criteria:
- Exclusion Criteria:
-
Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations
Celgene
Summit, New Jersey, United States
Not Provided
Celgene
NCT Number
Keywords
Expanded Access
Compassionate Use